Kelley Carly E, Ariel Danit
Division of Endocrinology, Metabolism, and Nutrition, Duke University, Durham, North Carolina.
Division of Endocrinology, Gerontology, and Metabolism, Stanford University School of Medicine, Stanford, California, USA.
Curr Opin Obstet Gynecol. 2025 Apr 1;37(2):83-96. doi: 10.1097/GCO.0000000000001013. Epub 2025 Feb 25.
This review aims to provide a comprehensive overview of the specific challenges, health considerations, and healthcare needs of transgender and gender diverse (TGD) people navigating menopause, highlighting the intersection of gender identity, hormone treatment, and age-related changes.
Research on menopause in TGD individuals is lacking, without guidelines to support clinical management. This is the first review of its type to summarize the described impact of the menopausal transition on TGD individuals, the potential long-term risks associated with both gender-affirming hormone therapy and the intersectionality with aging, and how these risks may impact hormone management and overall comprehensive care.
By drawing on the shared principles of cisgender menopausal hormone therapy and gender-affirming hormone therapy, providers are well positioned to apply their expertise to support the TGD population during menopause. We recommend using shared decision-making, culturally competent care, and a strong understanding of the biological, personal, and social experiences of TGD people that do not necessarily conform to stereotypically ciswoman experiences.
本综述旨在全面概述跨性别和性别多样化（TGD）人群在经历更年期时面临的具体挑战、健康考量及医疗保健需求，突出性别认同、激素治疗与年龄相关变化之间的交叉影响。
针对TGD个体的更年期研究匮乏，缺乏支持临床管理的指南。这是首次此类综述，总结了更年期过渡对TGD个体的已知影响、与性别确认激素疗法相关的潜在长期风险以及与衰老的交叉影响，以及这些风险如何影响激素管理和整体综合护理。
通过借鉴顺性别更年期激素疗法和性别确认激素疗法的共同原则，医疗服务提供者有能力运用其专业知识在更年期期间支持TGD人群。我们建议采用共同决策、具有文化胜任力的护理方式，并深入了解TGD人群不一定符合典型顺性别女性经历的生物学、个人和社会经历。
